🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NEW Research: #AI-guided detection of under-recognised cardiomyopathies on point-of-care cardiac ultrasonography. Evangelos K. Oikonomou Rohan Khera Read it here: buff.ly/3PZhhZH

Air pollution exposure and #cardiometabolic risk thelancet.com/journals/landi… type 2 #diabetes #T2D #AirPollution

#WorldCancerDay 📰Estimated worldwide variation and trends in incidence of #lungcancer by histological subtype in 2022 and over time Findings show the need for continued monitoring of the changing risk of lung cancer especially air pollution tinyurl.com/y2t8nurc

#WorldCancerDay 🆕analyses of🌍variations in #LungCancer incidence over time shows lung adenocarcinoma emerged as the predominant subtype in recent years, with increasing risks observed among younger generations in most countries assessed. The Lancet Respiratory Medicine iarc.who.int/news-events/gl…

NEW in The Lancet Respiratory Medicine for #WorldCancerDay📢 Study finds that lung adenocarcinoma has emerged as the predominant subtype of #lungcancer in recent years, driven by changes in smoking patterns and exposure to air pollution. Read more here! 👇 thelancet.com/journals/lanre…

The Lancet Respiratory Medicine has joined Bluesky! 🦋Find and follow us at bsky.app/profile/lancet… 🌐And, of course, online at thelancet.com/journals/lanre…

The proportion of never-smokers diagnosed with lung cancer is on the rise, new global analysis suggests in The Lancet Respiratory Medicine. Explore the research ▶️ hubs.li/Q0358LL-0 #WorldCancerDay IARC

Digital technologies (eg, smart inhalers) can be useful in research evaluating interventions in airways diseases, such as asthma. In The Lancet Respiratory Medicine, authors explore how digital technologies can potentially revolutionise the clinical trial process: hubs.li/Q036zc8q0

An elegant and comprehensive talk of immunotherapy for early-stage lung cancer by Molly Li for The Lancet Summit Cancer Control in China The Lancet Oncology The Lancet Respiratory Medicine The Lancet Gastroenterology & Hepatology

Approximately half of people who survive pulmonary tuberculosis will experience lung problems or breathing issues. A The Lancet Respiratory Medicine Review looks at strategies for prevention, diagnosis, & care for post-tuberculosis lung disease: hubs.li/Q03cTDKk0 #WorldTBDay

Understanding ICU care decisions 🏥 New publication in The Lancet Respiratory Medicine finds that patients with acute brain injuries are more likely to face earlier and more frequent withdrawal of life support than other ICU patients. Read more from UHN's Dr. Shaurya Taran ⬇️

🌍This week was #WorldTBDay. The Lancet Respiratory Medicine highlights that equitable, personalised medicine for tuberculosis is key to improving patient outcomes. 💊 Read more🔗: shorturl.at/F3Con

Thrilled to join The Lancet Commission on Serious Respiratory Illness & #PalliativeCare ! Together, we're rethinking palliative care's role in respiratory illness, especially in low- & middle-income countries. #PalliativeCare #RespiratoryIllness Led by our inspiring co-chairs,

Could it be time to move beyond traditional definitions of ARDS and rethink our approach to heterogeneity in ARDS care and research? 📖 Read it here authors.elsevier.com/a/1l0Mh7tFB1bV… 🙏 Huge thanks to my brilliant co-authors for their insight and collaboration.

Acute respiratory distress syndrome (ARDS) is a condition that affects people with severe breathing problems. A new paper in The Lancet Respiratory Medicine looks to refine the definition of ARDS, explores avenues to improve current understanding and improve treatment options:

🔥 Our take on trial design in cardiogenic shock led by Antoine Kimmoun, Connor O'Brien & Alexandre Mebazaa now out in The Lancet Respiratory Medicine 👉🏻 thelancet.com/journals/lanre… #biomarkers #AI Vanessa Blumer, MD, FACC Janine Pöss sabri soussi Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA Prof_Alain_COMBES Alessandro Sionis rebecca mathew SwissCardio

Our JAK inhibitors individual participant data meta-analysis just published. ⁦The Lancet⁩ ⁦The Lancet Respiratory Medicine⁩ Great collaborative effort ⁦Alain Amstutz🇨🇭🇱🇸⁩ ⁦Caio de Assis Moura Tavares⁩ Patricia Guimaraes and many other colleagues thelancet.com/journals/lanre…

🧵1/ Presented at #ASCO25: New phase 3 trial suggests adding lurbinectedin to first-line treatment extends survival in extensive-stage small cell lung cancer (ES-SCLC)—a deadly & difficult-to-treat disease. The trial identifies a clinically significant improvement in ES-SCLC